J. Reed

J. Reed

EVP, Innovative Medicine, R&DatJohnson & Johnson· In proxies 2023–2025

Pay in FY2025+31% from the year before

J. Reed was paid $12.2M in FY2025 (Dec), up 31%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Johnson & Johnson proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Johnson & JohnsonPublic company · 3 yr
    • EVP, Innovative Medicine, R&D2023 – Present · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?